Pod Insights Short Wave How a single flu shot could protect you for decades About this episode Every year, tens of millions of people in the U. S. get the flu vaccine. That’s because the virus changes year-to-year and protection only lasts around six months. Adolfo Garcia-Sastre https://profiles.icahn.mssm.edu/adolfo-garcia-sastre wants to change that. He’s one scientist working on a universal flu vaccine that could provide decades of protection against all flu illnesses – but only if his team can find the resources that disappeared when U. S. funding dipped.
If you liked this episode, listen to our episode on a vaccine trial that could end HIV https://lnk.to/BcnTUp.
Interested in more medical innovations? Email us your question at shortwave@npr.org mailto:shortwave@npr.org.
Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave http://plus.npr.org/shortwave.
See pcm.adswizz.com https://pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
NPR Privacy Policy https://www.npr.org/about-npr/179878450/privacy-policy
Transcript Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.
0:00 Speaker 00 This message comes from Doppel. Social engineering attacks come in disguise, but Doppel sees through them. The Agentic platform shuts down threats, turns employees into first-line defenders, and more. Learn more at D-O-P-P-E-L dot com.
0:16 Regina Barber? You're listening to Short Wave from NPR. The Centers for Disease Control and Prevention estimates that anywhere from 24,000 to 81,000 people died from the flu during this past flu season. Hundreds of thousands more were hospitalized and millions were infected. And this is a moderate season. In the event of a whole flu pandemic, those numbers could be much higher.
0:46 Speaker 02 There is more than 100 potential pandemic flu viruses that could start a pandemic.
0:51 Regina Barber? That's Adolfo Garcia Sastrick, a viral immunologist at the ICANN School of Medicine at Mount Sinai in New York. He's working on a vaccine that could not only protect people from a pandemic flu virus, but all flu viruses. No more annual flu shots. He calls it a universal flu vaccine.
1:10 Speaker 02 This shot that we are working on will protect not only against seasonal influenza, not only this year, not only against next year and next year and next year and this year, but also will prevent pandemic influenza from an animal reservoir.
1:28 Regina Barber? A vaccine like this hasn't been possible before because the virus that causes the flu, influenza, mutates every year, evading the previous year's vaccine. But he says-
1:40 Speaker 02 The virus cannot change completely. If not, we will not recognize it as influenza.
1:46 Regina Barber? And Adolfo and his team are working on a vaccine that can target all versions of the influenza virus, past, present, and future, if they can find the resources.
1:57 Regina Barber? Today on the show, the science behind a vaccine against all flus and what scientists need to make it a reality. I'm Regina Barber, and you're listening to Short Wave, the science podcast from NPR.
2:17 Speaker 03 Stay tuned for the following announcements and messages from our sponsors.
2:21 Speaker 00 This message comes from Found. Found provides modern business banking with built-in bookkeeping, invoices, contractor payments, and tax tools. Categorize expenses, track receipts, invoice clients, and send payments right where you bank. Join the hundreds of thousands who have already streamlined their finances with Found. Open a Found account for free at found.com. That's F-O-U-N-D dot com. Found is a financial technology company, not a bank. Banking services provided by Lead Bank, member FDIC.
2:51 Speaker 03 This message comes from International Medical Corps. When crises strike, every second matters, and that's why International Medical Corps moves fast. From the flooding in Nepal to earthquakes in Venezuela, they deliver lifesaving medical care and supplies around the world while training local health workers to ensure care continues long after the emergency ends. This giving season, your generosity saves lives and builds resilience for tomorrow. Learn more or donate today at internationalmedicalcorps.org/NPR.
3:24 Speaker 04 The NPR app cuts through the noise, bringing you local, national, and global coverage. No paywalls, no profits, no nonsense. Download it in your app store today.
3:39 Regina Barber? Okay, Adolfo, what about the flu virus impacts why we need a yearly vaccine?
3:44 Speaker 02 Yeah, so that's because the virus changes every year. And when we are talking about human influenza, we're talking about three viruses right now.
3:54 Regina Barber? Okay.
3:55 Speaker 02 And that's the reason why the vaccine has three components. So there is what they are called the influenza A and influenza B. A comes also in two shapes right now in humans that are called H1 and H3. And H refers to one of the proteins of the virus, the spike of the virus.
4:12 Regina Barber? Okay.
4:13 Speaker 02 This is called hemagglutinin. And that's H1 will be hemagglutinin subtype 1. H3 will be hemagglutinin subtype 3. All these three viruses are circulating in people. Some seasons, they are mainly H3s. Some seasons, they are mainly H1s. Some seasons, they are mainly B. But there is always... H1s, H3s and Bs causing infections in humans.
4:37 Regina Barber? Hmm, so flu A which comes into H subtypes and then Bs, okay.
4:42 Speaker 02 So we need three components, right? But each one of these viruses change every year. And they do so to avoid pre-existing immunity.
4:52 Regina Barber? Right.
4:52 Speaker 02 And the vaccine tries to cover the strains that are circulating. So we make the vaccine for whatever is going to be circulating this year. And the prediction come from the surveillance that has been done for influenza to see what is circulating at any time in the in the year. And sometimes we miss it for at least one of the components. This year, for example, we miss it. For H3s, there was this newest strain that became very quickly, very, very prevalent. And this one was not very well covered by the history component of the vaccine. Still, it provides you some some efficacy, but instead of having perhaps
5:35 Speaker 02 an efficacy of 70% prevention from a disease. Then it goes down to 30% because it's mismatched.
5:43 Regina Barber? Right, so all of this refers to current vaccine strategies, like what we do now. That's based on targeting parts of the viruses that change. But what you're working on is targeting regions that stay the same in the influenza virus in order to make this universal flu vaccine. One that we wouldn't need to get every year. Now, historically, there have been barriers to creating this kind of vaccine. What are they?
6:06 Speaker 02 So there are there are two types of barriers, the scientific barriers. And the other thing is is more about what type of resources you need to put, which is more of an economical reason than a scientific reason.
6:19 Regina Barber? Yeah.
6:20 Speaker 02 The scientific reason is because influenza has conserve areas.
6:25 Regina Barber? The parts of the influenza virus that doesn't change.
6:28 Speaker 02 They don't change, yeah, correct. That's what I mean by conserve. But not every conserve area is able to induce an immune response that will be able to protect. So you need to identify these ones that are able to protect. You know, it's like, um, just imagine, you know, that flu is a cow.
6:49 Regina Barber? It's a cow.
6:50 Speaker 02 So let's imagine it's a cow.
6:52 Regina Barber? Okay.
6:53 Speaker 02 So.
6:53 Regina Barber? Already there.
6:55 Speaker 02 So you wanna get protection from a cow, you need to target areas in the cow that will prevent damage to you, right? So perhaps you need to stop or cover the head with foam, let's say that, right? And then the cow cannot do damage.
7:11 Regina Barber? Right.
7:11 Speaker 02 Or the feet.
7:13 Regina Barber? Right.
7:13 Speaker 02 Then even if they kick you, they cannot do damage. But if you cover the tail, well, the cow cannot give you any damage with the tail.
7:22 Regina Barber? Right.
7:23 Speaker 02 So there are some areas in the virus that we call non-protective. So we need to find the protective areas
7:32 Regina Barber? Okay.
7:32 Speaker 02 of the virus that are conserved.
7:34 Regina Barber? And protective.
7:36 Speaker 02 Yeah.
7:36 Regina Barber? Okay.
7:36 Speaker 02 And then we need to induce an immune response against these conserve areas by designing a vaccine that is different from the ones that we have. Because the ones that we have only induce good responses against the variable areas.
7:50 Regina Barber? Variable areas, the parts of the virus that change.
7:53 Speaker 02 Yeah, which are very good, but they don't protect you against future strains. They don't protect you against pandemic strains.
7:59 Regina Barber? The science hasn't gotten here yet because we haven't been able to find those regions. Or.
8:06 Speaker 02 Well, it took a while.
8:06 Regina Barber? Okay.
8:07 Speaker 02 It took a while.
8:07 Regina Barber? Okay.
8:08 Speaker 02 Now we have some candidates.
8:09 Regina Barber? Okay, we have candidates and then we have to make a vaccine that will react to these regions that don't change.
8:16 Speaker 02 Yeah, correct.
8:17 Regina Barber? Okay, so your lab is working on a universal flu vaccine and you just finished phase one trial. What did phase one tell you?
8:24 Speaker 02 So phase one, the main thing that tells you is safety. And the second thing that tells you whether you get. The immune response that you think is good for the vaccine.
8:34 Regina Barber? Yeah, did you?
8:35 Speaker 02 Yeah.
8:35 Regina Barber? Wow.
8:36 Speaker 02 The phase one, we got induction of antibodies at levels that we think they will be protective. We have not been able to prove that in humans, but we think that the levels that we achieve, they will be protective.
8:49 Regina Barber? So have you started phase two?
8:51 Speaker 02 Phase two, we have not started. We are, we have been in phase one.
8:56 Regina Barber? What, what's holding up phase two?
8:59 Speaker 02 Uh, money, mainly money.
9:00 Regina Barber? Yeah.
9:01 Speaker 02 They are very costly and um, there was a NIH program that was called Civic that was for trying to get improved influenza vaccines. We were part of this program, but this program has been stopped. Uh, and, and right now it's unclear whether it's gonna restart.
9:22 Regina Barber? Was this part of the recent government cuts that happened in the last year?
9:27 Speaker 02 Well, it was not really a cut, but there has been also a lot of slowdown
9:33 Regina Barber? Hmm.
9:33 Speaker 02 in finances from NIH. So these contracts, they were supposed to at one moment bring clinical trials. But because funding stopped it and there is no call for new proposals yet. And if a call comes, because it takes time to review and then get funded, there's gonna be at least a gap of one year, two years.
9:58 Regina Barber? So what will happen to all your material, all those vaccines in that time?
10:02 Speaker 02 The, the problem with the vaccines that we are ready to go is that if they are not going, they need to maintain a stability program and this costs money, money that we don't have.
10:16 Regina Barber? Hmm.
10:16 Speaker 02 So we are trying to find partners outside NIH to finance for at least a stability program or if not also for some phase two, phase one clinical trials that we still need to do.
10:30 Regina Barber? How does that feel that you, you know, you could make something that could help so many people, but it get, it gets stopped by money?
10:38 Speaker 02 Well, it's frustrating, right? I think the money is there, but, but it's impossible to manage the program on time to be able to renew it again. Because of the amount of changes that have been in NIH. It's also the amount of money that has been put into this program already. You know, it's not trivial. And if we are not able to put this material that we have right now into humans, then it will be lost. And if we want to, in the future, to do it, we need to start again making this material.
11:14 Regina Barber? Are you optimistic that there will be this universal flu vaccine like created in your lifetime?
11:20 Speaker 02 In my lifetime, I hope so. But in the next five years, I think it's a big challenge. Because we want to prove not only that it prevents flu the year that we give the vaccine, but also prevents flu the second year, the third year, and the fourth year, right? So just to prove that we have a vaccine that protects for four years requires four years of follow up.
11:50 Regina Barber? So are you optimistic?
11:52 Speaker 02 I am. If not, I would not be working on it. But who knows? You know, I'm also trying not to become depressive at the end. This doesn't move forward, right? At least, you know, I really would love if we can prove that this is the way for a flu vaccine. But you know, to me, the discovery process, you know, to me is very exciting also, whether we can translate it into for the good of humanity even better. But just to find new mechanisms is very rewarding for scientists.
12:27 Regina Barber? Adolfo, thank you so much for talking to us today.
12:30 Speaker 02 OK, good.
12:34 Regina Barber? If you liked this episode, check out our episode on a vaccine trial that could end HIV. We'll put a link in our show notes. This episode was produced by Burley McCoy, edited by showrunner Rebecca Ramirez, and fact-checked by Tyler Jones. The audio engineer was Maggie Luthar. I'm Regina Barber. Thank you for listening to Short Wave from NPR.
13:04 Speaker 03 Stay tuned for the following announcements and messages from our sponsors.
13:09 Speaker 00 This message comes from Found. Found provides modern business banking with built-in bookkeeping, invoices, contractor payments, and tax tools. Categorize expenses, track receipts, invoice clients, and send payments right where you bank. Join the hundreds of thousands who have already streamlined their finances with Found. Open a Found account for free at found.com. That's F-O-U-N-D dot com. Found is a financial technology company, not a bank. Banking services provided by Lead Bank, member FDIC.
13:39 Speaker 05 The 2026 midterm elections are upon us. On November 3, voters will determine what the next two years of their local leadership and the balance of national government will look like. Listen to the NPR News Now podcast for all the updates you need ahead of and after November 3 from NPR News.
Previous Your DNA is changing all the time. Here’s why Next Why your sunscreen is finally getting a major upgrade Page updated October 30, 2026 · transcript and summary are machine-generated